中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 9
Sep.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(9): 2001-2005

Research advances in liver injury associated with chronic active Epstein-Barr virus disease

DOI: 10.12449/JCH260901

  • Department of Hematology，Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China

Research funding:

National Natural Science Foundation of China (82370185);

Beijing Clinical Key Specialty Project (2024);

Beijing Xicheng District Science and Technology Special Project (XCSTS-TI2024-38);

Beijing Natural Science Foundation (7262031);

Capital’s Funds for Health Improvement and Research (2026-2-1032)

More Information
  • Corresponding author: Wang Zhao， wangzhao@ccmu.edu.cn （ORCID： 0000-0003-1067-4589）
  • Received Date: 2026-08-17
  • Accepted Date: 2026-09-15
  • Published Date: 2026-09-25
    Abstract
  • Chronic active Epstein-Barr virus disease （CAEBVD） is a lymphoproliferative disorder caused by Epstein-Barr virus infection of T cells and natural killer cells. The liver is one of the most commonly affected organs in CAEBVD， with 47% to 67.1% of patients exhibiting varying degrees of liver injury. This article systematically reviews the characteristics of liver injury associated with CAEBVD from the aspects of its pathogenesis， clinical manifestations， pathological features， diagnostic criteria， treatment， and prognosis， in order to improve awareness of this disease among clinicians and promote early diagnosis and timely treatment.

     

    • FullText(HTML)
  • loading
    • References(46)
  • [1]
    Cohen J I. Epstein-Barr virus infection[J]. N Engl J Med, 2000, 343( 7): 481- 492. DOI: 10.1056/NEJM200008173430707.
    [2]
    Kawa K, Okamura T, Yagi K, et al. Mosquito allergy and Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease[J]. Blood, 2001, 98( 10): 3173- 3174. DOI: 10.1182/blood.v98.10.3173.
    [3]
    Quintanilla-Martinez L, Swerdlow S H, Tousseyn T, et al. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders[J]. Virchows Arch, 2023, 482( 1): 227- 244. DOI: 10.1007/s00428-022-03414-4.
    [4]
    Kimura H. EBV in T-/ NK-cell tumorigenesis[J]. Adv Exp Med Biol, 2018, 1045: 459- 475. DOI: 10.1007/978-981-10-7230-7_21.
    [5]
    Cohen J I, Jaffe E S, Dale J K, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: A 28-year experience in the United States[J]. Blood, 2011, 117( 22): 5835- 5849. DOI: 10.1182/blood-2010-11-316745.
    [6]
    Méndez-Sánchez N, Aguilar-Domínguez C, Chávez-Tapia N C, et al. Hepatic manifestations of Epstein-Barr viral infection[J]. Ann Hepatol, 2005, 4( 3): 205- 209.
    [7]
    Lin J, Su M F, Zheng J L, et al. Fas/FasL and complement activation are associated with chronic active epstein-barr virus hepatitis[J]. J Clin Transl Hepatol, 2023, 11( 3): 540- 549. DOI: 10.14218/JCTH.2022.00227.
    [8]
    Drebber U, Kasper H U, Krupacz J, et al. The role of Epstein-Barr virus in acute and chronic hepatitis[J]. J Hepatol, 2006, 44( 5): 879- 885. DOI: 10.1016/j.jhep.2006.02.006.
    [9]
    Li X J, Qu L J, Zheng X W, et al. Clinicopathologic features of chronic active Epstein-Barr virus hepatitis[J]. World Chin J Dig, 2013, 21( 23): 2325. DOI: 10.11569/wcjd.v21.i23.2325.
    [10]
    Wang J S, Su M, Wei N, et al. Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells[J]. Blood, 2024, 143( 1): 32- 41. DOI: 10.1182/blood.2023021074.
    [11]
    Hong M, Ko Y H, Yoo K H, et al. EBV-positive T/NK-cell lymphoproliferative disease of childhood[J]. Korean J Pathol, 2013, 47( 2): 137- 147. DOI: 10.4132/KoreanJPathol.2013.47.2.137.
    [12]
    Toner K, Bollard C M. EBV+ lymphoproliferative diseases: Opportunities for leveraging EBV as a therapeutic target[J]. Blood, 2022, 139( 7): 983- 994. DOI: 10.1182/blood.2020005466.
    [13]
    Collins P J, Fox C P, George L, et al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells[J]. Blood, 2021, 137( 2): 203- 215. DOI: 10.1182/blood.2020005611.
    [14]
    Kawada J I, Ito Y, Ohshima K, et al. Updated guidelines for chronic active Epstein–Barr virus disease[J]. Int J Hematol, 2023, 118( 5): 568- 576. DOI: 10.1007/s12185-023-03660-5.
    [15]
    Okuno Y, Murata T, Sato Y, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy[J]. Nat Microbiol, 2019, 4( 3): 404- 413. DOI: 10.1038/s41564-018-0334-0.
    [16]
    Jiang L, Gu Z H, Yan Z X, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma[J]. Nat Genet, 2015, 47( 9): 1061- 1066. DOI: 10.1038/ng.3358.
    [17]
    Murata T, Okuno Y, Sato Y, et al. Oncogenesis of CAEBV revealed: Intragenic deletions in the viral genome and leaky expression of lytic genes[J]. Rev Med Virol, 2020, 30( 2): e2095. DOI: 10.1002/rmv.2095.
    [18]
    Ohga S, Nomura A, Takada H, et al. Epstein-Barr virus(EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection[J]. J Infect Dis, 2001, 183( 1): 1- 7. DOI: 10.1086/317653.
    [19]
    Henter J I, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48( 2): 124- 131. DOI: 10.1002/pbc.21039.
    [20]
    Park J H, Noh J C, Park H M, et al. A case of Epstein-Barr virus infection with gall bladder and common bile duct stones in an otherwise healthy child[J]. Pediatr Gastroenterol Hepatol Nutr, 2012, 15( 1): 57. DOI: 10.5223/kjpgn.2012.15.1.57.
    [21]
    Lawee D. Mild infectious mononucleosis presenting with transient mixed liver disease: Case report with a literature review[J]. Can Fam Physician, 2007, 53( 8): 1314- 1316.
    [22]
    Markin R S. Manifestations of Epstein-Barr virus-associated disorders in liver[J]. Liver, 1994, 14( 1): 1- 13. DOI: 10.1111/j.1600-0676.1994.tb00001.x.
    [23]
    Zhou Zhe, Shao Lingyun, Zhang Wenhong. Progress in clinical diagnosis and treatment of chronic active Epstein-Barr virus infection[J]. J Clin Hematol, 2022, 35( 1): 11- 15.

    周哲, 邵凌云, 张文宏. 慢性活动性EB病毒感染临床诊断与治疗进展[J]. 临床血液学杂志, 2022, 35( 1): 11- 15.
    [24]
    Xu Jinghang, Yu Yanyan, Xu Xiaoyuan. Clinical features of Epstein-Barr virus infection associated to liver injury in adolescents and adults[J]. Chin J Hepatol, 2021, 29( 10): 915- 918. DOI: 10.3760/cma.j.cn501113-20210902-00445.

    徐京杭, 于岩岩, 徐小元. 青少年和成人EB病毒感染相关肝损伤的临床特征[J]. 中华肝脏病杂志, 2021, 29( 10): 915- 918. DOI: 10.3760/cma.j.cn501113-20210902-00445.
    [25]
    Mellinger J L, Rossaro L, Naugler W E, et al. Epstein–Barr virus(EBV) related acute liver failure: A case series from the US acute liver failure study group[J]. Dig Dis Sci, 2014, 59( 7): 1630- 1637. DOI: 10.1007/s10620-014-3029-2.
    [26]
    Suh N, Liapis H, Misdraji J, et al. Epstein-Barr virus hepatitis: Diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients[J]. Am J Surg Pathol, 2007, 31( 9): 1403- 1409. DOI: 10.1097/PAS.0b013e31802ffdd5.
    [27]
    Lymphocyte Group of Hematology Branch of the Chinese Medical Association; Hematology Group of Pediatrics Branch of the Chinese Medical Association; Infectious Disease Branch of the Chinese Medical Association. Expert consensus on diagnosis and treatment of chronic active Epstein-Barr virus disease(2025 edition)[J]. Natl Med J China, 2025, 105( 17): 1322- 1330. DOI: 10.3760/cma.j.cn112137-20241229-02956.

    中华医学会血液学分会淋巴细胞学组, 中华医学会儿科学分会血液学组, 中华医学会感染病学分会. 慢性活动性EB病毒病诊治专家共识(2025版)[J]. 中华医学杂志, 2025, 105( 17): 1322- 1330. DOI: 10.3760/cma.j.cn112137-20241229-02956.
    [28]
    Wang J S, Wang Y N, Wu L, et al. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis[J]. J Hematol Oncol, 2016, 9( 1): 84. DOI: 10.1186/s13045-016-0317-7.
    [29]
    Ma H H, Zhang L P, Wei A, et al. Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein–Barr virus infection[J]. Orphanet J Rare Dis, 2021, 16( 1): 269. DOI: 10.1186/s13023-021-01909-y.
    [30]
    Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection[J]. Bone Marrow Transplant, 2011, 46( 1): 77- 83. DOI: 10.1038/bmt.2010.122.
    [31]
    Yonese I, Sakashita C, Imadome K I, et al. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification[J]. Blood Adv, 2020, 4( 13): 2918- 2926. DOI: 10.1182/bloodadvances.2020001451.
    [32]
    Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: Prospective analysis of 108 cases[J]. Blood, 2012, 119( 3): 673- 686. DOI: 10.1182/blood-2011-10-381921.
    [33]
    Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection[J]. Int J Hematol, 2017, 105( 4): 406- 418. DOI: 10.1007/s12185-017-2192-6.
    [34]
    Arai A. Advances in the study of chronic active Epstein-Barr virus infection: Clinical features under the 2016 WHO classification and mechanisms of development[J]. Front Pediatr, 2019, 7: 14. DOI: 10.3389/fped.2019.00014.
    [35]
    Chen R Y, Lin Q, Zhu Y, et al. Sintilimab treatment for chronic active Epstein–Barr virus infection and Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children[J]. Orphanet J Rare Dis, 2023, 18( 1): 297. DOI: 10.1186/s13023-023-02861-9.
    [36]
    Ma Y X, Zhang P L, Bao Y H, et al. Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis[J]. Front Immunol, 2023, 14: 1093719. DOI: 10.3389/fimmu.2023.1093719.
    [37]
    Song Y, Wang J S, Wang Y N, et al. PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection[J]. Clin Microbiol Infect, 2023, 29( 6): 796.e7- 796.e13. DOI: 10.1016/j.cmi.2023.01.017.
    [38]
    Cui X L, Snapper C M. Epstein Barr virus: Development of vaccines and immune cell therapy for EBV-associated diseases[J]. Front Immunol, 2021, 12: 734471. DOI: 10.3389/fimmu.2021.734471.
    [39]
    Liu Y D, Cai J Y, Wang T Y, et al. Glycoprotein 350-targeted chimeric antigen receptor T-cell therapy for nonneoplastic chronic active Epstein-Barr virus infection: A case report[J]. Transl Pediatr, 2024, 13( 12): 2305- 2310. DOI: 10.21037/tp-24-292.
    [40]
    Yan S J, Ming X, Zhu X J, et al. Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease[J]. Front Immunol, 2024, 15: 1451977. DOI: 10.3389/fimmu.2024.1451977.
    [41]
    Yoshimori M, Shibayama H, Imadome K I, et al. Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection[J]. Blood Adv, 2021, 5( 7): 1805- 1815. DOI: 10.1182/bloodadvances.2020002417.
    [42]
    Shafiee A, Shamsi S, Kohandel Gargari O, et al. EBV associated T- and NK-cell lymphoproliferative diseases: A comprehensive overview of clinical manifestations and novel therapeutic insights[J]. Rev Med Virol, 2022, 32( 4): e2328. DOI: 10.1002/rmv.2328.
    [43]
    Arai A, Sakashita C, Hirose C, et al. Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: Efficacy and predictive markers[J]. Bone Marrow Transplant, 2016, 51( 6): 879- 882. DOI: 10.1038/bmt.2016.3.
    [44]
    Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection[J]. J Infect Dis, 2003, 187( 4): 527- 533. DOI: 10.1086/367988.
    [45]
    Lin J C, Chen X K, Wu H M, et al. Peripheral blood lymphocyte counts in patients with infectious mononucleosis or chronic active Epstein-Barr virus infection and prognostic risk factors of chronic active Epstein-Barr virus infection[J]. Am J Transl Res, 2021, 13( 11): 12797- 12806.
    [46]
    Chen S T, Wei A, Ma H H, et al. Clinical features and prognostic factors of children with chronic active Epstein-Barr virus infection: A retrospective analysis of a single center[J]. J Pediatr, 2021, 238: 268- 274. DOI: 10.1016/j.jpeds.2021.07.009.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (134) PDF downloads(112) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return